Key terms
About IRWD
Ironwood Pharmaceuticals, Inc. is a healthcare company, which engages in the development and commercialization of Gastrointestinal (GI) products. It operates through the Human Therapeutics segment. The company was founded on January 5, 1998 and is headquartered in Boston, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest IRWD news
Yesterday
2:37pm ET
Ironwood Pharmaceuticals: A Strong Buy on Promising Gastrointestinal Treatment Prospects and Market Expansion Opportunities
Yesterday
1:30pm ET
Analysts Are Bullish on Top Healthcare Stocks: Mediwound (MDWD), Ironwood Pharma (IRWD)
Yesterday
7:39am ET
Ironwood announces results from STARGAZE trial
Mar 22
11:07am ET
Jefferies retail/healthcare analysts to hold an analyst/industry conference call
Mar 16
12:36pm ET
Ironwood Pharmaceuticals (NASDAQ:IRWD): Analysts Stay Bullish Despite Recent Stock Plunge
Mar 01
12:55pm ET
Ironwood put volume heavy and directionally bearish
Mar 01
9:02am ET
Ironwood price target lowered to $18 from $21 at Craig-Hallum
Mar 01
8:37am ET
Ironwood Pharma: A Strong Buy on Apraglutide’s Success and Undervalued Market Potential
Mar 01
7:42am ET
Ironwood price target lowered to $14 from $20 at Wells Fargo
Feb 29
3:16pm ET
Ironwood Pharmaceuticals: Strong Buy Rating on LINZESS Performance and Apraglutide Market Potential
Feb 29
11:01am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Revance Therapeutics (RVNC), VYNE Therapeutics (VYNE) and Ironwood Pharma (IRWD)
Feb 29
9:30am ET
Analysts’ Top Healthcare Picks: Trulieve Cannabis (TCNNF), Avid Bioservices (CDMO)
Feb 29
6:24am ET
Ironwood reports ‘positive’ results from Phase III trial of apraglutide
Feb 26
12:30am ET
Analysts Offer Insights on Healthcare Companies: Blueprint Medicines (BPMC), AMN Healthcare Services (AMN) and Ironwood Pharma (IRWD)
Feb 22
10:14am ET
Jefferies biotechnology analysts hold an analyst/industry conference call
Feb 16
8:34am ET
Ironwood price target raised to $21 from $20 at Piper Sandler
Feb 15
3:10pm ET
Ironwood price target raised to $18 from $15 at Capital One
Feb 15
2:45pm ET
Ironwood Pharma: A Strong Buy on Solid Financials and a Promising Pipeline
Feb 15
2:06pm ET
Ironwood Pharmaceuticals Receives ‘Buy’ Rating from Analyst Amid Strong Performance and Promising Drug Pipeline
Feb 15
7:11am ET
Ironwood sees FY24 revenue $435M-$455M, consensus $462.82M
Feb 15
7:09am ET
Ironwood reports Q4 EPS 0c, consensus 21c
Feb 13
7:41am ET
Analysts Are Bullish on These Healthcare Stocks: Ironwood Pharma (IRWD), Gilead Sciences (GILD)
Feb 12
8:29am ET
Ironwood Pharma (IRWD) Gets a Buy from Craig-Hallum
Feb 12
4:55am ET
Piper Sandler healthcare analysts to hold an analyst/industry conference call
Feb 05
5:12pm ET
Piper Sandler healthcare analysts to hold an analyst/industry conference call
Jan 17
9:01am ET
Craig-Hallum bullish on Ironwood, initiates with a Buy
Jan 17
7:23am ET
Ironwood initiated with a Buy at Craig-Hallum
Jan 12
7:26am ET
Ironwood price target raised to $10.50 from $9 at TD Cowen
Jan 12
6:20am ET
Analysts Offer Insights on Healthcare Companies: Santhera Pharmaceuticals Holding (OtherSPHDF), Ironwood Pharma (IRWD) and Cytokinetics (CYTK)
Jan 08
8:05pm ET
Ironwood Pharma: A Strong Buy on Robust Sales Growth and Promising Pipeline
Jan 08
7:00pm ET
Ironwood announces publication of Phase III study in The Lancet
No recent news articles are available for IRWD
IRWD Financials
Key terms
Ad Feedback
IRWD Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
IRWD Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range